The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.90
Bid: 1.80
Ask: 2.00
Change: 0.375 (24.59%)
Spread: 0.20 (11.111%)
Open: 1.525
High: 1.90
Low: 1.90
Prev. Close: 1.525
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

1 Jun 2023 11:00

RNS Number : 3512B
Shield Therapeutics PLC
01 June 2023
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:

Shield Therapeutics plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

x

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

x

Other (please specify) iii:

3. Details of person subject to the notification obligation iv

Name

Nutrition-Wellness Venture SA

City and country of registered office (if applicable)

Vevey, Switzerland

4. Full name of shareholder(s) (if different from 3.) v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reached vi:

16 March 2023 and 9 May 2023 (post AOP conversion)

6. Date on which issuer notified (DD/MM/YYYY):

25 May 2023

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer (8.A + 8.B) vii

Resulting situation on the date on which threshold was crossed or reached

7.85%

0%

7.85%

56,008,541

Position of previous notification (if

applicable)

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rights ix

% of voting rights

Direct

(DTR5.1)

Indirect

 (DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BYV81293

56,008,541

0

7.85%

0%

SUBTOTAL 8. A

56,008,541

7.85%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdate x

Exercise/Conversion Period xi

Physical or cash

Settlement xii

Number of voting rights

% of voting rights

 

SUBTOTAL 8.B.2

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv

X

Name xv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Nestle S.A.

7.85%

7.85%

 

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional information xvi

 

Place of completion

Vevey, Switzerland

Date of completion

31 May 2023

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLFBMLTMTIMMPJ
Date   Source Headline
25th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
24th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
23rd May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
22nd May 20231:25 pmRNSForm 8.3 - Shield Therapeutics PLC
19th May 20234:17 pmRNSForm 8.3 - Shield Therapeutics Plc
19th May 20232:29 pmRNSForm 8.3 – Shield Therapeutics plc
19th May 20237:00 amRNS2022 Annual Report and 2023 AGM Notice
18th May 20233:15 pmRNSForm 8 (OPD) - Shield Therapeutics plc
18th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
17th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
17th May 20237:15 amEQSHardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q’23 Accrufer prescriptions
16th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
12th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
11th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
10th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
9th May 20235:20 pmRNSForm 8 (OPD) - Shield Therapeutics plc
9th May 20234:00 pmRNSRule 2.9 Announcement and TVR Update
9th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
9th May 202311:04 amGNWForm 8.3 - Shield Therapeutics plc
5th May 20233:09 pmRNSForm 8 (DD) - Shield Therapeutics Plc
5th May 202312:00 pmRNSForm 8.5 (EPT/RI) - Shield Therapeutics Plc
5th May 202311:55 amRNSForm 8.3 - SHIELD THERAPEUTICS PLC
4th May 20232:40 pmRNSAOP Loan Conversion and Mandatory Cash Offer
27th Apr 20237:00 amRNSBusiness Update and Unaudited Results
12th Apr 20237:00 amRNSNotice of Results
5th Apr 20237:00 amRNSAppointment of Chief Commercial Officer
31st Mar 20237:00 amRNSBlock Listing 6 Monthly Return
15th Mar 20234:35 pmRNSPrice Monitoring Extension
28th Feb 20237:00 amRNSTotal Voting Rights Update
17th Feb 202311:05 amRNSSecond Price Monitoring Extn
17th Feb 202311:00 amRNSPrice Monitoring Extension
9th Feb 20234:40 pmRNSSecond Price Monitoring Extn
9th Feb 20234:35 pmRNSPrice Monitoring Extension
9th Feb 20239:05 amRNSSecond Price Monitoring Extn
9th Feb 20239:00 amRNSPrice Monitoring Extension
9th Feb 20237:00 amRNSFull Year Trading Update
23rd Jan 202311:15 amEQSHardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital
13th Jan 202310:30 amRNSHolding(s) in Company
13th Jan 20237:16 amEQSHardman & Co Research: Shield Therapeutics (STX) - Positioned for growth and profitability
12th Jan 20232:40 pmRNSHolding(s) in Company
12th Jan 20232:15 pmRNSHolding(s) in Company
9th Jan 20235:10 pmRNSPartial AOP Loan Conversion
9th Jan 20233:56 pmRNSHolding(s) in Company
9th Jan 20233:25 pmRNSHolding(s) in Company
5th Jan 20233:45 pmRNSResult of General Meeting & Open Offer
28th Dec 20227:00 amRNSTotal Voting Rights Update
28th Dec 20227:00 amRNSPDMR Transaction Notification
16th Dec 20227:00 amRNSPublication of Circular &Notice of General Meeting
13th Dec 20223:45 pmRNSSuccessful completion of US$18.5m Equity Fundraise
13th Dec 20227:02 amRNSInvestor presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.